<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487678</url>
  </required_header>
  <id_info>
    <org_study_id>KEsupplements</org_study_id>
    <nct_id>NCT04487678</nct_id>
  </id_info>
  <brief_title>Exogenous Ketones in People With Type 1 Diabetes</brief_title>
  <official_title>A Single-centre, Randomised, Single-blinded Crossover Study Evaluating the Metabolic Effects of a Ketone Ester Food Supplement in People With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to investigate the metabolic effects of exogenous ketone ester
      food supplements, by assessing the change in blood acid-base balance, and the level of blood
      beta-hydroxy-butyrate in people with type 1 diabetes during resting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ketone bodies acetoacetate, β‐hydroxybutyrate (βHB) and acetone are small lipid-derived
      molecules that are produced in the liver under certain conditions such as starvation, very
      low carbohydrate intake and prolonged glycogen-depleting exercise (Robinson and Williamson,
      1980, Balasse and Fery, 1989). Ketone bodies serve as an alternative energy substrate for the
      brain and other metabolically active tissues under periods of low glucose availability, and
      can modulate carbohydrate and lipid metabolism. Previously, controlled physiological ketosis
      required a low carbohydrate diet, starvation or administration of acetoacetate (AcAc) salts
      which were all unpleasant or potentially harmful. The development of ketone esters provides
      an alternative method to increase βHB levels, and has been shown to be well tolerated in
      rodents and humans (Cox et al., 2016, Clarke et al., 2012, Kesl et al., 2016). Two examples
      are the R,S-1,3-butanediol acetoacetate diester (Kesl et al., 2016) and the
      (R)-3-hydroxybutyl (R)-3-hydroxybutyrate ketone monoester (Clarke et al., 2012, Cox et al.,
      2016). Ingestion of either have been shown to result in short-term (0.5-6 hours) nutritional
      ketosis (βHB &gt;1mM) (Clarke et al., 2012, Kesl et al., 2016). Nutritional ketosis can
      therefore be achieved without the need for the impracticality of ketogenic dieting or
      fasting.

      In recent years there has been considerable interest in ketone body food supplements due to
      their potential for improved exercise performance (Pinckaers et al., 2017, Evans et al.,
      2017, Egan and D'Agostino, 2016) and therapeutic glucose lowering effects in people with type
      2 diabetes (Myette-Cote et al., 2018, Egan, 2018). Exogenous ketone supplements may be of
      particular interest for individuals living with type 1 diabetes by serving as an alternative
      fuel substrate to reduce the reliance on glucose utilisation and spare endogenous glycogen
      (Cox and Clarke, 2014) and reduce the risk of hypoglycaemia in certain situations, such as
      exercise. Stubbs et al. (2017) found that drinks containing exogenous ketones were a
      practical and efficacious way to raise blood βHB levels with only a modest change in
      acid-base balance in healthy individuals without diabetes (after 60 min, blood pH declined
      from 7.41 to 7.31 following a ketone ester drink). To date, no studies have investigated the
      metabolic effects of ketone in people with type 1 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single-centre, randomised, single blinded, crossover study in 6 individuals with type 1 diabetes (see inclusion/exclusion criteria)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>There will be two intervention arms that will take place in a randomised, single blinded fashion so that participants are not aware of which dose of ketone esters they receive</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in venous blood pH</measure>
    <time_frame>Over a 3 hour period from baseline following ingestion of a ketone ester drink in people with type 1 diabetes.</time_frame>
    <description>Change in blood pH over a 3 hour period from baseline following ingestion of a ketone ester drink</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood total ketone level /beta hydroxy butyrate level</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose concentration</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substrate oxidation rates determined using indirect calorimetry, via RER (respiratory exchange ratio)</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal distress symptoms via a questionnaire</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Ketosis, Diabetic</condition>
  <arm_group>
    <arm_group_label>Low-dose KE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>141 mg/kg bodyweight of ketone esters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose KE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>282 mg/kg bodyweight of ketone esters</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone ester supplement</intervention_name>
    <description>Participants taking part in this study will receive a drink containing either 141 or 282 mg/kg bodyweight of ketone esters in a randomised order. These doses are in line with recommendations by the company HVMN from which the supplements for this study will be obtained.</description>
    <arm_group_label>High-dose KE</arm_group_label>
    <arm_group_label>Low-dose KE</arm_group_label>
    <other_name>H.V.M.N Ketone Ester food supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes for &gt;1 year

          -  Male and female aged 18-45 years old

          -  HbA1c &lt;8.5% (69 mmol/mol) based on analysis from the central laboratory unit of Bern
             University Hospital

          -  Using either continuous subcutaneous insulin infusion or multiple daily injections

          -  Wearing a continuous glucose monitor (CGM) or flash glucose monitor (fGM)

          -  Written informed consent

        Exclusion Criteria:

          -  Physical or psychological disease likely to interfere with the normal conduct of the
             study and interpretation of the results as judged by the investigator

          -  Current treatment with drugs known to interfere with metabolism e.g. systemic
             corticosteroids, statins, SGLT2 inhibitors, GLP1 agonists

          -  Relevant diabetic complications as judged by the investigator

          -  Body mass index &gt; 30 kg/m2

          -  Uncontrolled hypertension (&gt;180/100 mmHg)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Stettler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Stettler, MD</last_name>
    <phone>+41 (0)31 632 40 70</phone>
    <email>Christoph.Stettler@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sam Scott, PhD</last_name>
    <email>sam.scott@extern.insel.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christoph Stettler, MD</last_name>
      <email>christoph.stettler@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sam Scott, PhD</last_name>
      <email>sam.scott@extern.insel.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Balasse EO, Féry F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989 May;5(3):247-70. Review.</citation>
    <PMID>2656155</PMID>
  </reference>
  <reference>
    <citation>Clarke K, Tchabanenko K, Pawlosky R, Carter E, Todd King M, Musa-Veloso K, Ho M, Roberts A, Robertson J, Vanitallie TB, Veech RL. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012 Aug;63(3):401-8. doi: 10.1016/j.yrtph.2012.04.008. Epub 2012 May 3.</citation>
    <PMID>22561291</PMID>
  </reference>
  <reference>
    <citation>Cox PJ, Clarke K. Acute nutritional ketosis: implications for exercise performance and metabolism. Extrem Physiol Med. 2014 Oct 29;3:17. doi: 10.1186/2046-7648-3-17. eCollection 2014. Review.</citation>
    <PMID>25379174</PMID>
  </reference>
  <reference>
    <citation>Cox PJ, Kirk T, Ashmore T, Willerton K, Evans R, Smith A, Murray AJ, Stubbs B, West J, McLure SW, King MT, Dodd MS, Holloway C, Neubauer S, Drawer S, Veech RL, Griffin JL, Clarke K. Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metab. 2016 Aug 9;24(2):256-68. doi: 10.1016/j.cmet.2016.07.010. Epub 2016 Jul 27.</citation>
    <PMID>27475046</PMID>
  </reference>
  <reference>
    <citation>Egan B. The glucose-lowering effects of exogenous ketones: is there therapeutic potential? J Physiol. 2018 Apr 15;596(8):1317-1318. doi: 10.1113/JP275938. Epub 2018 Mar 24.</citation>
    <PMID>29473164</PMID>
  </reference>
  <reference>
    <citation>Egan B, D'Agostino DP. Fueling Performance: Ketones Enter the Mix. Cell Metab. 2016 Sep 13;24(3):373-375. doi: 10.1016/j.cmet.2016.08.021.</citation>
    <PMID>27626197</PMID>
  </reference>
  <reference>
    <citation>Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation. J Physiol. 2017 May 1;595(9):2857-2871. doi: 10.1113/JP273185. Epub 2016 Dec 7. Review.</citation>
    <PMID>27861911</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Kesl SL, Poff AM, Ward NP, Fiorelli TN, Ari C, Van Putten AJ, Sherwood JW, Arnold P, D'Agostino DP. Effects of exogenous ketone supplementation on blood ketone, glucose, triglyceride, and lipoprotein levels in Sprague-Dawley rats. Nutr Metab (Lond). 2016 Feb 4;13:9. doi: 10.1186/s12986-016-0069-y. eCollection 2016.</citation>
    <PMID>26855664</PMID>
  </reference>
  <reference>
    <citation>Myette-Côté É, Neudorf H, Rafiei H, Clarke K, Little JP. Prior ingestion of exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance test in healthy young individuals. J Physiol. 2018 Apr 15;596(8):1385-1395. doi: 10.1113/JP275709. Epub 2018 Mar 2. Erratum in: J Physiol. 2019 Nov;597(22):5515. Abstract corrected.</citation>
    <PMID>29446830</PMID>
  </reference>
  <reference>
    <citation>Pinckaers PJ, Churchward-Venne TA, Bailey D, van Loon LJ. Ketone Bodies and Exercise Performance: The Next Magic Bullet or Merely Hype? Sports Med. 2017 Mar;47(3):383-391. doi: 10.1007/s40279-016-0577-y.</citation>
    <PMID>27430501</PMID>
  </reference>
  <reference>
    <citation>Robinson AM, Williamson DH. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol Rev. 1980 Jan;60(1):143-87. Review.</citation>
    <PMID>6986618</PMID>
  </reference>
  <reference>
    <citation>Stubbs BJ, Cox PJ, Evans RD, Santer P, Miller JJ, Faull OK, Magor-Elliott S, Hiyama S, Stirling M, Clarke K. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017 Oct 30;8:848. doi: 10.3389/fphys.2017.00848. eCollection 2017.</citation>
    <PMID>29163194</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

